Nordic Laboratories

PATIENT: **XXXXXXXXXXXXXXXX**　　TEST REF: **TST-NL-XXXX**

TEST NUMBER: T-NL-XXXXX (XXXXXXXXX)　　COLLECTED: XX/XX/XXXX　　PRACTITIONER:
GENDER: XYZ　　RECEIVED: XX/XX/XXXX　　**XXXXXXXXXXX**
AGE: XX　　TESTED: XX/XX/XXXX

XXXXXXXXXXXXXXXXXXXXX

TEST NAME: GI Effects Comprehensive Profile (GIFX)

2200 GI Effects™ Comprehensive Profile - Stool

Powered by **Genova AI**

Results Overview

- MALDIGESTION
- INFLAMMATION
- INFECTION
- DYSBIOSIS
- METABOLITE IMBALANCE
- DIGESTION
- INFLAMMATION
- GUT MICROBIOME

## Functional Imbalance Scores

Key (< 2) : Low Need for Support　(2-3) : Optional Need for Support　(4-6) : Moderate Need for Support　(7-10) : High Need for Support

Need for Digestive Support	Need for Inflammation Modulation	Need for Microbiome Support	Need for Prebiotic Support	Need for Antimicrobial Support
MALDIGESTION	**INFLAMMATION**	**DYSBIOSIS**	**METABOLIC IMBALANCE**	**INFECTION**
5	**10**	**10**	**0**	**10**

Biomarkers

Pancreatic Elastase ▽	Calprotectin ▲	IAD/Methane Score ▲	Total SCFA's ●	Parasitic Infection ▲
Products of Protein Breakdown ●	Eosinophil Protein X ▲	PP Bacteria/Yeast ▲	n-Butyrate Conc. ●	PP Bacteria/Yeast ▲
Fecal Fats ●	Secretory IgA ●	Reference Variance ▲	SCFA (%) ●	Total Abundance △
	Occult Blood ●	Total Abundance △	Beta-glucuronidase ●	Pathogenic Bacteria ●

Therapeutic Support Options

• Digestive Enzymes • Betaine HCl • Bile Salts • Apple Cider Vinegar • Mindful Eating Habits • Digestive Bitters	• Elimination Diet/ Food Sensitivity Testing • Mucosa Support: Slippery Elm, Althea, Aloe, DGL, etc. • Zinc Carnosine • L-Glutamine • Quercetin • Turmeric • Omega-3's • GI Referral (If Calpro is Elevated)	• Pre-/Probiotics • Increase Dietary Fiber Intake • Consider SIBO Testing • Increase Resistant Starches • Increase Fermented Foods • Meal Timing	• Pre-/Probiotics • Increased Dietary Fiber Intake • Increase Resistant Starches • increase Fermented Foods • Calcium D-Glucarate (for high beta-glucuronidase)	• Antibiotics (if warranted) • Antimicrobial Herbal Therapy • Antiparasitic Herbal Therapy (if warranted) • *Saccharomyces boulardii*

Nordic Laboratories Aps
Nygade 6, 3.sal • 1164 Copenhagen K • Denmark
Tlf. +45 33 75 10 00

UK Office:
11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK
Tel: +44 (0)1580 201 687

Page 1 of 11
www.nordic-labs.com
info@nordic-labs.com

PATIENT: **XXXXXXXXXXXXXXXX**   TEST REF: **TST-NL-XXXX**

TEST NUMBER: T-NL-XXXXX (XXXXXXXXXX)   COLLECTED: XX/XX/XXXX   PRACTITIONER:
GENDER: XYZ   RECEIVED: XX/XX/XXXX   **XXXXXXXXXXXXXX**
AGE: XX   TESTED: XX/XX/XXXX

XXXXXXXXXXXXXXXXXXXXXX

Nordic Laboratories

TEST NAME: GI Effects Comprehensive Profile (GIFX)

Commensal Microbiome Analysis

Commensal Abundance

Patient Total Commensal Abundance

-30%   -10%   +10%   You   +30%

Healthy Cohort

Potential Microbiome Deficiency   100%   Potential Microbiome Overgrowth

Total Commenal Balance: The total commensal abundance is a sum-total of the reported commensal bacteria compared to a healthy cohort. Low levels of commensal bacteria are often observed after antimicrobial therapy, or in diets lacking fiber and/or prebiotic-rich foods and may indicate the need for microbiome support. Conversely, higher total commensal abundance may indicate potential bacteria overgrowth or probiotic supplementation.

Dysbiosis Patterns

Inflammation-Associated Dysbiosis (IAD)   36
30   110
Low   High

Methane Dysbiosis Score   9
5   16
Low   High

Dysbiosis Patterns: Genova's data analysis has led to the development of unique dysbiosis patterns, related to key physiologic disruptions, such as immunosuppresion and inflammation. These patterns may represent dysbiotic changes that could pose clinical significance. Please see Genova's published literature for more details: https://rdcu.be/bRhzv

Zone 1: The commensal profile in this zone does not align with profiles associated with intestinal inflammation or immunosuppression. If inflammatory biomarkers are present, other causes need to be excluded, such as infection, food allergy, or more serious pathology.

Zone 2: This pattern of bacteria is associated with impaired intestinal barrier function (low fecal sIgA and EPX). Patients in this zone have higher rates of opportunistic infections (e.g. *Blastocystis spp.* & *Dientamoeba fragilis*) as well as fecal fat malabsorption. Commensal abundance is higher in this group suggesting potential bacterial overgrowth.

Zone 3: Patients in this zone may have more inflammation compared to those in zone 4. However, commensal abundance is usually higher making use of antimicrobial therapy relatively safer. Patients in this zone may have higher rates of pathogenic infections.

Zone 4: This commensal profile is associated with increased intestinal inflammation. IBD patients are more likely to have this pattern of bacteria. Commensal abundance is lower in this zone; therefore, antibiotic use for GI potential pathogens should be used with caution. In addition to standard treatment for intestinal inflammation, modulation of the commensal gut profile is encouraged.

Nordic Laboratories Aps
Nygade 6, 3.sal • 1164 Copenhagen K • Denmark
Tlf. +45 33 75 10 00

UK Office:
11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK
Tel: +44 (0)1580 201 687

Page 2 of 11
www.nordic-labs.com
info@nordic-labs.com

PATIENT: **XXXXXXXXXXXXXXXX**　　TEST REF: **TST-NL-XXXX**

TEST NUMBER: T-NL-XXXXX (XXXXXXXXXX)　COLLECTED: XX/XX/XXXX　PRACTITIONER:
GENDER: XYZ　RECEIVED: XX/XX/XXXX　**XXXXXXXXXXXXXX**
AGE: XX　TESTED: XX/XX/XXXX

XXXXXXXXXXXXXXXXXXXXXX

Nordic Laboratories

TEST NAME: GI Effects Comprehensive Profile (GIFX)

Commensal Microbiome Analysis

## Commensal Balance

Balanced	Represents 95% of healthy individuals
Borderline	Represents 5% of healthy individuals
Imbalanced	Represents 60% of unhealthy individuals

*A progressive ranking scale based on a Genova proprietary algorithm that differentiates healthy and unhealthy commensal patterns.

**The total number of Commensal Bacteria (PCR) that are out of reference ranges for this individual.

Relative Commensal Abundance

Phylum	Description
Bacteroidetes Phylum	Increase in *Bacteroides spp.* and *Odoribacter spp.* seen in animal-based diets; *Prevotella* increased with plant-based diet
Firmicutes Phylum	Contains many butyrate-producers; most species responsive to plant-based diets; *Faecalibacterium spp.* is anti-inflammatory
Actinobacteria Phylum	*Bifidobacterium* is increased with plant-based diets; *Collinsella* may be proinflammatory, and is elevated with a Western-diet
Proteobacteria Phylum	Some species may be proinflammatory; *E. coli* consumes simple sugars and is lower in individuals on plant-based diets
Euryarchaeota Phylum ***	*Methanobrevibacter smithii* is associated with methane production and with diets high in carbohydrates
Fusobacteria Phylum	Certain *Fusobacterium spp.* may be proinflammatory and increased on low fiber, high fat diets
Verrucomicrobia Phylum	*Akkermansia spp.* is involved in gut membrane integrity and may be increased with polyphenols and prebiotics

Relative Abundance: The relative abundance compares the quantity of each of 7 major bacterial phyla to a healthy cohort. This can indicate broader variances in the patient's gut microbiome profile. Certain interventions may promote or limit individual phyla when clinically appropriate. Please refer to Genova's Stool Testing Support Guide for more information on modulation of commensal bacteria through diet & nutrient interventions. ***Roughly 75% of the healthy cohort had below detectable levels of *Methanobrevibacter smithii.*

Physician Notes/Recommendations

Nordic Laboratories Aps
Nygade 6, 3.sal • 1164 Copenhagen K • Denmark
Tlf. +45 33 75 10 00

UK Office:
11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK
Tel: +44 (0)1580 201 687

Page 3 of 11
www.nordic-labs.com
info@nordic-labs.com

PATIENT: **XXXXXXXXXXXXXXXX**	TEST REF: **TST-NL-XXXX**
TEST NUMBER: T-NL-XXXXX (XXXXXXXXXX)	PRACTITIONER:
GENDER: XYZ	**XXXXXXXXXXXX**
AGE: XX	
COLLECTED: XX/XX/XXXX	XXXXXXXXXXXXXXXXXXXXXX
RECEIVED: XX/XX/XXXX	
TESTED: XX/XX/XXXX	

TEST NAME: GI Effects Comprehensive Profile (GIFX)

2200 GI Effects™ Comprehensive Profile - Stool

Methodology: GC/MS, Automated Chemistry, EIA

	Result	QUINTILE DISTRIBUTION (1st–5th)	Reference Range

Digestion and Absorption

	Result		Reference Range
Pancreatic Elastase 1 †	158 L		>200 mcg/g
Products of Protein Breakdown (Total*) (Valerate, Isobutyrate, Isovalerate)	6.0		1.8-9.9 micromol/g
Fecal Fat (Total*)	19.5		3.2-38.6 mg/g
Triglycerides	1.1		0.3-2.8 mg/g
Long-Chain Fatty Acids	12.9		1.2-29.1 mg/g
Cholesterol	0.5		0.4-4.8 mg/g
Phospholipids	5.0		0.2-6.9 mg/g

Inflammation and Immunology

	Result		Reference Range
Calprotectin †	145 H		<=50 mcg/g
Eosinophil Protein X (EPX)†	4.9 H		<=4.6 mcg/g
Fecal secretory IgA	206		<=885 mcg/g

Gut Microbiome Metabolites

Metabolic

	Result		Reference Range
Short-Chain Fatty Acids (SCFA) (Total*) (Acetate, n-Butyrate, Propionate)	81.3		>=23.3 micromol/g
n-Butyrate Concentration	18.1		>=3.6 micromol/g
n-Butyrate %	22.3		11.8-33.3 %
Acetate %	63.1		48.1-69.2 %
Propionate %	14.6		<=29.3 %
Beta-glucuronidase	2,297		368-6,266 U/g

*Total value is equal to the sum of all measurable parts.

†These results are not represented by quintile values.

Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless otherwise noted with ♦, the assays have not been cleared by the U.S. Food and Drug Administration.

Nordic Laboratories Aps
Nygade 6, 3.sal • 1164 Copenhagen K • Denmark
Tlf. +45 33 75 10 00

UK Office:
11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK
Tel: +44 (0)1580 201 687

Page 4 of 11
www.nordic-labs.com
info@nordic-labs.com

PATIENT: **XXXXXXXXXXXXXXXX**

TEST REF: **TST-NL-XXXX**

TEST NUMBER: T-NL-XXXXX (XXXXXXXXX)
GENDER: XYZ
AGE: XX

COLLECTED: XX/XX/XXXX
RECEIVED: XX/XX/XXXX
TESTED: XX/XX/XXXX

PRACTITIONER:
XXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXX

Nordic Laboratories

TEST NAME: GI Effects Comprehensive Profile (GIFX)

Methodology: DNA by PCR

Gastrointestinal Microbiome (PCR)**

Commensal Bacteria (PCR)	Result CFU/g stool	Quintile Distribution	Reference Range CFU/g stool
Bacteroidetes Phylum			
Bacteroides-Prevotella group	2.4E8		3.4E6-1.5E9
Bacteroides vulgatus	1.2E9		<=2.2E9
Barnesiella spp.	3.6E7		<=1.6E8
Odoribacter spp.	7.1E7		<=8.0E7
Prevotella spp.	1.4E8 H		1.4E5-1.6E7
Firmicutes Phylum			
Anaerotruncus colihominis	3.4E7 H		<=3.2E7
Butyrivibrio crossotus	5.0E7 H		5.5E3-5.9E5
Clostridium spp.	2.1E8		1.7E8-1.5E10
Coprococcus eutactus	1.0E8		<=1.2E8
Faecalibacterium prausnitzii	7.5E8		5.8E7-4.7E9
Lactobacillus spp.	1.6E8		8.3E6-5.2E9
Pseudoflavonifractor spp.	3.0E8 H		4.2E5-1.3E8
Roseburia spp.	7.6E7 L		1.3E8-1.2E10
Ruminococcus spp.	1.9E9 H		9.5E7-1.6E9
Veillonella spp.	1.5E8 H		1.2E5-5.5E7
Actinobacteria Phylum			
Bifidobacterium spp.	1.5E8		<=6.4E9
Bifidobacterium longum	1.4E8		<=7.2E8
Collinsella aerofaciens	5.1E8		1.4E7-1.9E9
Proteobacteria Phylum			
Desulfovibrio piger	8.7E7 H		<=1.8E7
Escherichia coli	1.3E8 H		9.0E4-4.6E7
Oxalobacter formigenes	5.0E7 H		<=1.5E7
Euryarchaeota Phylum			
Methanobrevibacter smithii	1.4E8 H		<=8.6E7
Fusobacteria Phylum			
Fusobacterium spp.	2.3E7 H		<=2.4E5
Verrucomicrobia Phylum			
Akkermansia muciniphila	3.1E7		>=1.2E6
Firmicutes/Bacteroidetes Ratio			
Firmicutes/Bacteroidetes (F/B Ratio)	11 L		12-620

Quintile Distribution columns: 1st, 2nd, 3rd, 4th, 5th

The gray-shaded portion of a quintile reporting bar represents the proportion of the reference population with results below detection limit.

Commensal results and reference range values are displayed in a computer version of scientific notation, where the capital letter "E" indicates the exponent value (e.g., 7.3E6 equates to 7.3×10^6 or 7,300,000).

The Firmicutes/Bacteroidetes ratio (F/B Ratio) is estimated by utilizing the lowest and highest values of the reference range for individual organisms when patient results are reported as <DL or >UL.

PATIENT: **XXXXXXXXXXXXXXXX**

TEST NUMBER: T-NL-XXXXX (XXXXXXXXXX)
GENDER: XYZ
AGE: XX

COLLECTED: XX/XX/XXXX
RECEIVED: XX/XX/XXXX
TESTED: XX/XX/XXXX

TEST REF: **TST-NL-XXXX**

PRACTITIONER:
XXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXX

Nordic Laboratories

TEST NAME: GI Effects Comprehensive Profile (GIFX)

Methodology: Culture/MALDI-TOF MS, Automated and Manual Biochemical Methods, Vitek® 2 System Microbial identification and Antibiotic susceptibility

Gastrointestinal Microbiome (Culture)

Human microflora is influenced by environmental factors and the competitive ecosystem of the organisms in the GI tract. Pathogenic significance should be based upon clinical symptoms.

Additional Bacteria

Non-Pathogen: Organisms that fall under this category are those that constitute normal, commensal flora, or have not been recognized as etiological agents of disease.
Potential Pathogen: Organisms that fall under this category are considered potential or opportunistic pathogens when present in heavy growth.
Pathogen: The organisms that fall under this category have a well-recognized mechanism of pathogenicity in clinical literature and are considered significant regardless of the quantity that appears in the culture.

Microbiology Legend

NG	NP	PP	P
No Growth	Non-Pathogen	Potential Pathogen	Pathogen

Bacteriology (Culture)

Lactobacillus spp.	2+	NP	
Escherichia coli	4+	NP	
Bifidobacterium	2+	NP	

Additional Bacteria

|			
alpha haemolytic Streptococcus	4+	NP	
Klebsiella pneumoniae	4+	PP	

Mycology (Culture)

Candida species	3+	PP	

KOH Preparation for Yeast

Methodology: Potassium Hydroxide (KOH) Preparation for Yeast

Potassium Hydroxide (KOH) Preparation for Yeast
These yeast usually represent the organisms isolated by culture. In the presence of a negative yeast culture, microscopic yeast may reflect organisms not viable enough to grow in culture. The presence of yeast on KOH prep should be correlated with the patient's symptoms. However, moderate to many yeast suggests yeast overgrowth.

Result

KOH Preparation, stool — Few Yeast Present

The result is reported as the amount of yeast seen microscopically:
Rare: 1-2 per slide
Few: 2-5 per high power field (HPF)
Moderate: 5-10 per HPF
Many: >10 per HPF

PATIENT: **XXXXXXXXXXXXXXXX**

TEST NUMBER: T-NL-XXXXX (XXXXXXXXXX)
GENDER: XYZ
AGE: XX

COLLECTED: XX/XX/XXXX
RECEIVED: XX/XX/XXXX
TESTED: XX/XX/XXXX

TEST REF: **TST-NL-XXXX**

PRACTITIONER:
XXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXX

TEST NAME: GI Effects Comprehensive Profile (GIFX)

Parasitology

Microscopic O&P Results

Microscopic O&P is capable of detecting all described gastrointestinal parasites. The organisms listed in the box represent those commonly found in microscopic stool analysis. Should an organism be detected that is not included in the list below, it will be reported in the Additional Results section.

Genus/species	Result
Nematodes - roundworms	
Ancylostoma/Necator (Hookworm)	Not Detected
Ascaris lumbricoides	Not Detected
Capillaria philippinensis	Not Detected
Enterobius vermicularis	Not Detected
Strongyloides stercoralis	Not Detected
Trichuris trichiura	Not Detected
Cestodes - tapeworms	
Diphyllobothrium latum	Not Detected
Dipylidium caninum	Not Detected
Hymenolepis diminuta	Not Detected
Hymenolepis nana	Not Detected
Taenia spp.	Not Detected
Trematodes - flukes	
Clonorchis/Opisthorchis spp.	Not Detected
Fasciola spp./ *Fasciolopsis buski*	Not Detected
Heterophyes/Metagonimus	Not Detected
Paragonimus spp.	Not Detected
Schistosoma spp.	Not Detected
Protozoa	
Balantidium coli	Not Detected
Blastocystis spp.	**Rare Detected**
Chilomastix mesnili	Not Detected
Cryptosporidium spp.	Not Detected
Cyclospora cayetanensis	Not Detected
Dientamoeba fragilis	**Moderate Detected**
Entamoeba coli	Not Detected
Entamoeba histolytica/dispar	Not Detected
Entamoeba hartmanii	Not Detected
Entamoeba polecki	Not Detected
Endolimax nana	Not Detected
Giardia	Not Detected
Iodamoeba buetschlii	Not Detected
Cystoisospora spp.	Not Detected
Trichomonads (e.g. *Pentatrichomonas*)	Not Detected
Additional Findings	
White Blood Cells	Not Detected
Charcot-Leyden Crystals	Not Detected
Other Infectious Findings	

One negative specimen does not rule out the possibility of a parasitic infection.

Nordic Laboratories Aps

Nygade 6, 3.sal • 1164 Copenhagen K • Denmark

Tlf. +45 33 75 10 00

UK Office:

11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK

Tel: +44 (0)1580 201 687

Page 7 of 11

www.nordic-labs.com

info@nordic-labs.com

Nordic Laboratories

TEST NAME: GI Effects Comprehensive Profile (GIFX)

Parasitology

PCR Parasitology - Protozoa**

Methodologies: DNA by PCR, Next Generation Sequencing

Organism	Result	Units		Expected Result
Blastocystis spp.	6.00e2	femtograms/microliter C&S stool	Detected	Not Detected
Cryptosporidium parvum/hominis	<1.76e2	genome copies/microliter C&S stool	Not Detected	Not Detected
Cyclospora cayetanensis	<2.65e2	genome copies/microliter C&S stool	Not Detected	Not Detected
Dientamoeba fragilis	6.40e2	genome copies/microliter C&S stool	Detected	Not Detected
Entamoeba histolytica	<9.64e1	genome copies/microliter C&S stool	Not Detected	Not Detected
Giardia	<1.36e1	genome copies/microliter C&S stool	Not Detected	Not Detected

Additional Results

Methodology: Fecal Immunochemical Testing (FIT)

	Result	Expected Value
Fecal Occult Blood◆	Negative	Negative
Color††	Green	
Consistency††	Formed/Normal	

††Results provided from patient input.

Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless otherwise noted with ◆, the assays have not been cleared by the U.S. Food and Drug Administration.

Zonulin Family Peptide

Methodology: EIA

	Result	Reference Range
Zonulin Family Peptide, Stool	100.0	22.3-161.1 ng/mL

Zonulin Family Peptide

This test is for research use only. Genova will not provide support on interpreting the test results. This test does not detect zonulin.[1] The Scheffler paper suggests that the IDK kit may detect a zonulin family peptide, such as properdin. Genova's unpublished data demonstrated that the current IDK kit results were associated with stool inflammation biomarkers and an inflammation-associated dysbiosis profile.

The performance characteristics of Zonulin Family Peptide have been verified by Genova Diagnostics, Inc. The assay has not been cleared by the U.S. Food and Drug Administration.

Reference:

1. Scheffler L, et al. Widely Used Commercial ELISA Does Not Detect Precursor of Haptoglobin2, but Recognizes Properdin as a Potential Second Member of the Zonulin Family. *Front Endocrinol.* 2018;9:22.

PATIENT: **XXXXXXXXXXXXXXXX**

TEST NUMBER: T-NL-XXXXX (XXXXXXXXX)
GENDER: XYZ
AGE: XX

COLLECTED: XX/XX/XXXX
RECEIVED: XX/XX/XXXX
TESTED: XX/XX/XXXX

TEST REF: **TST-NL-XXXX**

PRACTITIONER:
XXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXX

Nordic Laboratories

TEST NAME: GI Effects Comprehensive Profile (GIFX)

Macroscopic/Direct Exam for Parasites

Methodology: Macroscopic Evaluation

No human parasite detected in sample.

Add-on Testing

Methodology: EIA

	Result	Expected Value
HpSA - *H. pylori*	Negative	Negative
Campylobacter spp.♦**	Negative	Negative
Clostridium difficile♦**	Negative	Negative
Shiga toxin *E. coli*♦**	Negative	Negative
Fecal Lactoferrin♦**	Negative	Negative

HpSA (*Helicobacter pylori* stool antigen)

Helicobacter pylori is a bacterium which causes peptic ulcer disease and plays a role in the development of gastric cancer. Direct stool testing of the antigen (HpSA) is highly accurate and is appropriate for diagnosis and follow-up of infection.

Clostridium difficile

Clostridium difficile is an anaerobic, spore-forming gram-positive bacterium. After a disturbance of the gut flora (usually with antibiotics), colonization with *Clostridium difficile* can take place. *Clostridium difficile* infection is much more common than once thought.

Shiga toxin *E. coli*

Shiga toxin-producing *Escherichia coli* (STEC) is a group of bacterial strains that have been identified as worldwide causes of serious human gastrointestinal disease. The subgroup enterohemorrhagic *E. coli* includes over 100 different serotypes, with 0157:H7 being the most significant, as it occurs in over 80% of all cases. Contaminated food continues to be the principal vehicle for transmission; foods associated with outbreaks include alfalfa sprouts, fresh produce, beef, and unpasteurized juices.

Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless otherwise noted with ♦, the assays have not been cleared by the U.S. Food and Drug Administration.

Nordic Laboratories Aps
Nygade 6, 3.sal • 1164 Copenhagen K • Denmark
Tlf. +45 33 75 10 00

UK Office:
11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK
Tel: +44 (0)1580 201 687

Page 9 of 11
www.nordic-labs.com
info@nordic-labs.com

PATIENT: **XXXXXXXXXXXXXXXX**

TEST REF: **TST-NL-XXXX**

TEST NUMBER: T-NL-XXXXX (XXXXXXXXXX)
GENDER: XYZ
AGE: XX

COLLECTED: XX/XX/XXXX
RECEIVED: XX/XX/XXXX
TESTED: XX/XX/XXXX

PRACTITIONER:
XXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXX

TEST NAME: GI Effects Comprehensive Profile (GIFX)

Methodology: Vitek 2® System Microbial Antibiotic susceptibility, Manual Minimum Inhibition Concentration

Mycology Sensitivity

Azole Antifungals

Candida species	R	I	S-DD	S	NI
Fluconazole				0.5	
Voriconazole				<=0.008	
Nystatin	=50				

Natural Agents

Candida species	LOW INHIBITION .... HIGH INHIBITION
Berberine	
Caprylic Acid	
Garlic	
Undecylenic Acid	
Plant tannins	
Uva-Ursi	

Prescriptive Agents:

The R (Resistant) category implies isolate is not inhibited by obtainable levels of pharmaceutical agent.

The I (Intermediate) category includes isolates for which the minimum inhibition concentration (MIC) values usually approach obtainable pharmaceutical agent levels and for which response rates may be lower than for susceptible isolates.

The S-DD (Susceptible-Dose Dependent) category implies clinical efficacy when higher than normal dosage of a drug can be used and maximal concentration achieved.

The S (Susceptible) column implies that isolates are inhibited by the usually achievable concentrations of the pharmaceutical agent.

NI (No Interpretive guidelines established) category is used for organisms that currently do not have established guidelines for MIC interpretation.

Refer to published pharmaceutical guidelines for appropriate dosage therapy.

Nystatin and Natural Agents:

Results for Nystatin are being reported with natural antifungals in this category in accordance with laboratory guidelines for reporting sensitivities. In this assay, inhibition is defined as the reduction level on organism growth as a direct result of inhibition by a natural substance. The level of inhibition is an indicator of how effective the substance was at limiting the growth of an organism in an in vitro environment. High inhibition indicates a greater ability by the substance to limit growth, while Low Inhibition a lesser ability to limit growth. The designated natural products should be considered investigational in nature and not be viewed as standard clinical treatment substances.

Nordic Laboratories Aps
Nygade 6, 3.sal • 1164 Copenhagen K • Denmark
Tlf. +45 33 75 10 00

UK Office:
11 Old Factory Buildings • Stonegate • E. Sussex TN5 7DU • UK
Tel: +44 (0)1580 201 687

Page 10 of 11
www.nordic-labs.com
info@nordic-labs.com

PATIENT: **XXXXXXXXXXXXXXXX**

TEST NUMBER: T-NL-XXXXX (XXXXXXXXX)
GENDER: XYZ
AGE: XX

COLLECTED: XX/XX/XXXX
RECEIVED: XX/XX/XXXX
TESTED: XX/XX/XXXX

TEST REF: **TST-NL-XXXX**

PRACTITIONER:
XXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXX

Nordic Laboratories

TEST NAME: GI Effects Comprehensive Profile (GIFX)

Methodology: Vitek 2® System Microbial Antibiotic susceptibility, Manual Minimum Inhibition Concentration

Bacteria Sensitivity

Prescriptive Agents

Klebsiella pneumoniae	R	I	S-DD	S	NI
Ampicillin	R				
Amox./Clavulanic Acid				S	
Cephalothin				S	
Ciprofloxacin				S	
Tetracycline				S	
Trimethoprim/Sulfa				S	

Natural Agents

Klebsiella pneumoniae	LOW INHIBITION ──────────────── HIGH INHIBITION
Berberine	
Oregano	
Plant Tannins	
Uva-Ursi	

Prescriptive Agents:
The R (Resistant) category implies isolate is not inhibited by obtainable levels of pharmaceutical agent.
The I (Intermediate) category includes isolates for which the minimum inhibition concentration (MIC) values usually approach obtainable pharmaceutical agent levels and for which response rates may be lower than for susceptible isolates.
The S-DD (Susceptible-Dose Dependent) category implies clinical efficacy when higher than normal dosage of a drug can be used and maximal concentration achieved.
The S (Susceptible) column implies that isolates are inhibited by the usually achievable concentrations of the pharmaceutical agent.
NI (No Interpretive guidelines established) category is used for organisms that currently do not have established guidelines for MIC interpretation.
Refer to published pharmaceutical guidelines for appropriate dosage therapy.
Natural Agents:
In this assay, inhibition is defined as the reduction level on organism growth as a direct result of inhibition by a substance. The level of inhibition is an indicator of how effective the substance was at limiting the growth of an organism in an in vitro environment. High inhibition indicates a greater ability by the substance to limit growth, while Low Inhibition a lesser ability to limit growth. The designated natural products should be considered investigational in nature and not be viewed as standard clinical treatment substances.

Page 11 of 11
www.nordic-labs.com
info@nordic-labs.com